Genprex to Present TUSC2 Gene Therapy Research on Cellular Aging at GSA Meeting
Bitget2026/10/28 11:08- Genprex will present TUSC2 research Nov. 4, 2026, at the Gerontological Society of America’s annual scientific meeting.
- Research with Meharry Medical College describes a cellular-resilience response to TUSC2 gene therapy in humans; TUSC2 is used in cancer candidate Reqorsa.
- The findings could inform potential applications beyond oncology, but additional research is needed to determine whether they support therapeutic development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
